Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

JS207 Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)

NCT07045311 is registered in ClinicalTrials.gov with Shanghai Junshi Bioscience Co., Ltd. as lead sponsor.

NCT NCT07045311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07045311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
JS207 Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
Lead sponsor
Shanghai Junshi Bioscience Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
September 17, 2025
Completion date
March 22, 2029
Enrollment
80 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer